RCKT · Insider Trading
Rocket Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by RCKT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Martin Wilson | General Counsel | Sell | −75,364 | −$256.46K |
| 2026-08-20 | Gaurav Shah | CEO | Sell | −2,293 | −$7.75K |
| 2026-08-20 | Martin Wilson | General Counsel | Sell | −631 | −$2.13K |
| 2026-08-17 | Martin Wilson | General Counsel | Sell | −3,493 | −$11.81K |
| 2026-08-17 | Gaurav Shah | CEO | Sell | −2,837 | −$9.59K |
| 2026-08-13 | Sarbani Chaudhuri | See Remarks | Sell | −4,701 | −$16.45K |
| 2026-08-13 | Christopher James Stevens | Chief Operating Officer | Sell | −36,658 | −$128.27K |
| 2026-08-05 | Christopher James Stevens | Chief Operating Officer | A | +73,313 | — |
| 2026-08-05 | David P Southwell | Director | J | +150,000 | — |
| 2026-07-06 | Mikael Dolsten | Director | A | +22,862 | — |
| 2026-07-06 | Fady Ibraham Malik | Director | A | +22,862 | — |
| 2026-07-06 | Carsten Boess | Director | A | +22,862 | — |
| 2026-07-06 | Peter Fong | Director | A | +22,862 | — |
| 2026-07-06 | David P Southwell | Director | A | +22,862 | — |
| 2026-07-06 | Roderick Wong | Director | A | +27,832 | — |
| 2023-02-22 | John Militello | See Remarks | M | +2,858 | — |
| 2023-02-22 | Gaurav Shah | CEO | Sell | −12,194 | −$232.42K |
| 2023-02-22 | Gaurav Shah | CEO | M | +31,440 | — |
| 2023-02-22 | Jonathan David Schwartz | See Remarks | M | +8,574 | — |
| 2023-02-22 | John Militello | See Remarks | Sell | −1,244 | −$23.71K |
| 2023-02-22 | Kinnari Patel | See Remarks | M | +15,720 | — |
| 2023-02-22 | Jonathan David Schwartz | See Remarks | Sell | −3,557 | −$67.80K |
| 2023-02-16 | John Militello | See Remarks | A | +66,414 deriv. | — |
| 2023-02-16 | Jonathan David Schwartz | See Remarks | A | +166,037 deriv. | — |
| 2023-02-16 | Kinnari Patel | See Remarks | A | +265,661 deriv. | — |
| 2023-02-16 | Martin Wilson | General Counsel | A | +116,226 deriv. | — |
| 2023-02-16 | Gaurav Shah | CEO | A | +464,907 deriv. | — |
| 2022-12-23 | Roderick Wong | Director | J | +2 deriv. | — |
| 2022-12-22 | RTW INVESTMENTS, LP | Director | J | +2 deriv. | — |
| 2022-10-11 | Roderick Wong | Director | Buy | +2,711,864 | +$40.00M |
| 2022-08-16 | John Militello | See Remarks | A | +14,310 deriv. | — |
| 2022-08-16 | Martin Wilson | General Counsel | A | +49,081 deriv. | — |
| 2022-08-16 | Kinnari Patel | See Remarks | A | +52,489 deriv. | — |
| 2022-08-16 | Jonathan David Schwartz | See Remarks | A | +22,896 deriv. | — |
| 2022-06-15 | Naveen Yalamanchi | Director | A | +47,745 deriv. | — |
| 2022-06-15 | Fady Ibraham Malik | Director | A | +47,745 deriv. | — |
| 2022-06-15 | David P Southwell | Director | A | +47,745 deriv. | — |
| 2022-06-15 | Elisabeth Bjork | Director | A | +55,090 deriv. | — |
| 2022-06-15 | Gotham Makker | Director | A | +53,621 deriv. | — |
| 2022-06-15 | Roderick Wong | Director | A | +53,621 deriv. | — |
| 2022-06-15 | Carsten Boess | Director | A | +47,745 deriv. | — |
| 2022-06-15 | Pedro P Granadillo | Director | A | +58,028 deriv. | — |
| 2022-04-20 | John Militello | See Remarks | A | +47,964 deriv. | — |
| 2022-04-04 | Jonathan David Schwartz | See Remarks | Sell | −135,000 | −$2.19M |
| 2022-04-01 | Jonathan David Schwartz | See Remarks | Sell | −45,000 | −$738.65K |
| 2022-03-11 | Fady Ibraham Malik | Director | A | +41,840 deriv. | — |
| 2022-03-09 | Gotham Makker | Director | G | −621,500 | — |
| 2022-02-16 | Carlos Garcia-Parada | Chief Financial Officer | A | +71,328 deriv. | — |
| 2022-02-16 | Jonathan David Schwartz | See Remarks | A | +106,994 deriv. | — |
| 2022-02-16 | Kinnari Patel | See Remarks | A | +196,155 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Roderick Wong | Director | 18,263,956 | $41.64M |
| Gaurav Shah | CEO | 1,254,935 | $2.86M |
| Martin Wilson | General Counsel | 598,489 | $1.36M |
| Christopher James Stevens | Chief Operating Officer | 505,784 | $1.15M |
| David P Southwell | Director | 317,646 | $724.23K |
| Sarbani Chaudhuri | See Remarks | 262,809 | $599.20K |
| Peter Fong | Director | 76,195 | $173.72K |
| Mikael Dolsten | Director | 67,082 | $152.95K |
| Carsten Boess | Director | 52,862 | $120.53K |
| Fady Ibraham Malik | Director | 52,862 | $120.53K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RCKT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.